MediWound Ltd. (NASDAQ:MDWD) sees strong growth in short-term interest


MediWound Ltd. (NASDAQ: MDWDGet a rating) benefited from significant growth in short-term interest during the month of May. As of May 31, there were short interests totaling 62,600 shares, a growth of 47.6% from the total of 42,400 shares as of May 15. About 0.3% of the stock’s shares are sold short. Based on an average trading volume of 92,000 shares, the day-to-cover ratio is currently 0.7 days.

Several institutional investors have recently increased or reduced their stake in the company. ARK Investment Management LLC increased its stake in MediWound shares by 9.1% in the 4th quarter. ARK Investment Management LLC now owns 834,166 shares of the biopharmaceutical company valued at $1,969,000 after acquiring an additional 69,290 shares during the period. Sargent Investment Group LLC increased its stake in MediWound shares by 2.5% in Q1. Sargent Investment Group LLC now owns 374,750 shares of the biopharmaceutical company valued at $746,000 after purchasing an additional 9,000 shares last quarter. Wells Fargo & Company MN increased its equity stake in MediWound by 12.3% in Q4. Wells Fargo & Company MN now owns 322,677 shares of the biopharmaceutical company valued at $762,000 after buying 35,238 additional shares last quarter. Meitav Dash Investments Ltd. increased its stake in MediWound by 56.1% in the 1st quarter. Meitav Dash Investments Ltd. now owns 306,538 shares of the biopharmaceutical company valued at $607,000 after acquiring an additional 110,129 shares in the last quarter. Finally, Morgan Stanley increased its stake in MediWound by 12.4% in the third quarter. Morgan Stanley now owns 85,947 shares of the biopharmaceutical company valued at $287,000 after acquiring 9,497 additional shares in the last quarter. 13.58% of the shares are currently held by institutional investors and hedge funds.

A number of equity analysts have weighed in on MDWD shares recently. StockNews.com began covering MediWound shares in a research report on Tuesday. They put a “sell” mark on the stock. Wells Fargo & Company raised its price target on MediWound stock to $8.00 and gave the stock an “overweight” rating in a Wednesday, May 18 research report. Finally, Aegis lowered its price target on MediWound shares from $9.00 to $7.00 and set a “buy” rating on the stock in a Monday, March 21 research report.

MDWD Stock traded down $0.11 in Tuesday’s trading, hitting $1.66. 664 shares were traded, against an average volume of 42,818. The company has a 50-day moving average price of $1.96 and a 200-day moving average price of $2.21. MediWound has a 1 year minimum of $1.25 and a 1 year maximum of $6.22. The company has a market capitalization of $55.01 million, a price-earnings ratio of -3.39 and a beta of 1.25.

MediWound (NASDAQ: MDWDGet a rating) last reported results on Tuesday, May 17. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing analyst consensus estimates of ($0.11) by ($0.01). MediWound had a negative return on equity of 3,540.43% and a negative net margin of 64.01%. The company posted revenue of $4.41 million for the quarter, versus $4.35 million expected by analysts. During the same period last year, the company made ($0.10) earnings per share. Sell-side analysts expect MediWound to post -0.38 EPS for the current fiscal year.

About MediWound (Get a rating)

MediWound Ltd., a biopharmaceutical company, develops, manufactures and markets innovative, biotherapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, dead or damaged tissue in adults with partial and total deep thermal burns to burn treatment centers and burn units in hospitals.

Further reading



Get news and reviews for MediWound Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for MediWound and related companies with MarketBeat.com’s FREE daily newsletter.

Comments are closed.